Skip to main content

Development of Antibody Therapeutics against Flaviviruses

Abstract Recent outbreaks of Zika virus (ZIKV) highlight the urgent need to develop efficacious interventions against flaviviruses, many of which cause devastating epidemics around the world. Monoclonal antibodies (mAb) have been at the forefront of treatment for cancer and a wide array of other diseases due to their specificity and potency. While mammalian cell-produced mAbs have shown promise as therapeutic candidates against several flaviviruses, their eventual approval for human application still faces several challenges including their potential risk of predisposing treated patients to more severe secondary infection by a heterologous flavivirus through antibody-dependent enhancement (ADE). The high cost associated with mAb production in mammal... (more)
Created Date 2017-12-25
Contributor Sun, Haiyan (ASU author) / Chen, Qiang (ASU author) / Lai, Huafang (ASU author) / Biodesign Institute / College of Liberal Arts and Sciences / School of Life Sciences / Infectious Diseases and Vaccinology
Type Text
Extent 26 pages
Language English
Identifier DOI: 10.3390/ijms19010054 / ISSN: 1661-6596 / ISSN: 1422-0067
Reuse Permissions
Citation Sun, H., Chen, Q., & Lai, H. (2017). Development of Antibody Therapeutics against Flaviviruses. International Journal of Molecular Sciences, 19(1), 54. doi:10.3390/ijms19010054
Collaborating Institutions ASU Library
Additional Formats MODS / OAI Dublin Core / RIS

  Development of Antibody Therapeutics_2018.pdf
1.9 MB application/pdf
Download Count: 163